TY - JOUR
T1 - Patients with primary membranous nephropathy are at high risk of cardiovascular events
AU - Lee, Taewoo
AU - Derebail, Vimal K.
AU - Kshirsagar, Abhijit V.
AU - Chung, Yunro
AU - Fine, Jason P.
AU - Mahoney, Shannon
AU - Poulton, Caroline J.
AU - Lionaki, Sophia
AU - Hogan, Susan L.
AU - Falk, Ronald J.
AU - Cattran, Daniel C.
AU - Hladunewich, Michelle
AU - Reich, Heather N.
AU - Nachman, Patrick H.
N1 - Publisher Copyright:
© 2016 International Society of Nephrology.
PY - 2016/5/1
Y1 - 2016/5/1
N2 - Here we conducted a retrospective study to examine the risk of cardiovascular events (CVEs) relative to that of end-stage renal disease (ESRD) in patients with primary membranous nephropathy, in a discovery cohort of 404 patients. The cumulative incidence of CVEs was estimated in the setting of the competing risk of ESRD with risk factors for CVEs assessed by multivariable survival analysis. The observed cumulative incidences of CVEs were 4.4%, 5.4%, 8.2%, and 8.8% at 1, 2, 3, and 5 years respectively in the primary membranous nephropathy cohort. In the first 2 years after diagnosis, the risk for CVEs was similar to that of ESRD in the entire cohort, but exceeded it among patients with preserved renal function. Accounting for traditional risk factors and renal function, the severity of nephrosis at the time of the event (hazard ratio 2.1, 95% confidence interval 1.1 to 4.3) was a significant independent risk factor of CVEs. The incidence and risk factors of CVEs were affirmed in an external validation cohort of 557 patients with primary membranous nephropathy. Thus early in the course of disease, patients with primary membranous nephropathy have an increased risk of CVEs commensurate to, or exceeding that of ESRD. Hence, reduction of CVEs should be considered as a therapeutic outcome measure and focus of intervention in primary membranous nephropathy.
AB - Here we conducted a retrospective study to examine the risk of cardiovascular events (CVEs) relative to that of end-stage renal disease (ESRD) in patients with primary membranous nephropathy, in a discovery cohort of 404 patients. The cumulative incidence of CVEs was estimated in the setting of the competing risk of ESRD with risk factors for CVEs assessed by multivariable survival analysis. The observed cumulative incidences of CVEs were 4.4%, 5.4%, 8.2%, and 8.8% at 1, 2, 3, and 5 years respectively in the primary membranous nephropathy cohort. In the first 2 years after diagnosis, the risk for CVEs was similar to that of ESRD in the entire cohort, but exceeded it among patients with preserved renal function. Accounting for traditional risk factors and renal function, the severity of nephrosis at the time of the event (hazard ratio 2.1, 95% confidence interval 1.1 to 4.3) was a significant independent risk factor of CVEs. The incidence and risk factors of CVEs were affirmed in an external validation cohort of 557 patients with primary membranous nephropathy. Thus early in the course of disease, patients with primary membranous nephropathy have an increased risk of CVEs commensurate to, or exceeding that of ESRD. Hence, reduction of CVEs should be considered as a therapeutic outcome measure and focus of intervention in primary membranous nephropathy.
KW - cardiovascular disease
KW - glomerulonephritis
KW - membranous nephropathy
UR - http://www.scopus.com/inward/record.url?scp=84964596900&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84964596900&partnerID=8YFLogxK
U2 - 10.1016/j.kint.2015.12.041
DO - 10.1016/j.kint.2015.12.041
M3 - Article
C2 - 26924046
AN - SCOPUS:84964596900
SN - 0085-2538
VL - 89
SP - 1111
EP - 1118
JO - Kidney international
JF - Kidney international
IS - 5
ER -